Natural Capsules Preferential Issue (13 Nov 2026)
Natural Capsules Limited approves Q2 2026 results and preferential allotment
Natural Capsules · Pharmaceuticals & Biotechnology
Key highlights
- Board approved unaudited consolidated and standalone financial results for Q2 and H1 ended Sept 30, 2026, on Nov 13, 2026
- Preferential allotment approved for 1,12,500 equity shares at ₹178 each, totaling ₹22.52 crore, to promoter Mr. Sunil L Mundra
- Preferential allotment approved for 4,50,000 fully convertible warrants at ₹178 each, aggregating ₹8.01 crore, to same promoter
Original filing
Announcement under Regulation 30 (LODR)-Allotment
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Natural Capsules
Other fundraise / allotment filings this fortnight
- Fundraise / allotmentUnited Heat TransferUnited Heat Transfer Limited approves half-year financial results for Sept 2026
- Fundraise / allotmentJubilant PharmovaJubilant Pharmova reports Q2 and H1 FY27 financial results and operational updates
- Fundraise / allotmentDestiny Logistics & InfraDestiny Logistics & Infra Ltd announces key resignations, appointments, and warrant lapse
- Fundraise / allotmentShalimar PaintsShalimar Paints Limited announces QIP Committee approval for equity shares issue
- Fundraise / allotmentOrchid PharmaOrchid Pharma Limited QIP proceeds utilization and monitoring report for Q2 FY 2026-27
- Fundraise / allotmentS J Logistics (India)SJL announces preferential issue of equity shares and warrants to raise ₹92.58 crore
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.